Traditional SLE biomarkers like anti-double-stranded DNA, anti-Smith and C3/C4 often lack the sensitivity needed for early diagnosis, leading to multiyear delays in treatment. These delays result in irreversible organ damage, prolonged corticosteroid dependency and increased healthcare costs. Analysing over 3000 subjects across 14 years, this study proves the Multianalyte Assay Panel (MAP) index identifies 24.5% more SLE cases than conventional tests alone.
Daniel Wallace
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack